Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Nicholas J. Short; Elias Jabbour; Maher Albitar; Marcos de Lima; Lia Gore; Jeffrey Jorgensen; Aaron C. Logan; Jae Park; Farhad Ravandi; Bijal Shah; Jerald Radich; Hagop Kantarjian

doi:10.1002/ajh.25338

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Nicholas J. Short, Elias Jabbour, Maher Albitar, Marcos de Lima, Lia Gore, Jeffrey Jorgensen, Aaron C. Logan, Jae Park, Farhad Ravandi, Bijal Shah, Jerald Radich, Hagop Kantarjian

Research output: Contribution to journal › Review article › peer-review

83 Scopus citations

Abstract

Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.

Original language	English (US)
Pages (from-to)	257-265
Number of pages	9
Journal	American journal of hematology
Volume	94
Issue number	2
DOIs	https://doi.org/10.1002/ajh.25338
State	Published - Feb 2019

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25338

Cite this

Short, N. J., Jabbour, E., Albitar, M., de Lima, M., Gore, L., Jorgensen, J., Logan, A. C., Park, J., Ravandi, F., Shah, B., Radich, J., & Kantarjian, H. (2019). Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. American journal of hematology, 94(2), 257-265. https://doi.org/10.1002/ajh.25338

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. / Short, Nicholas J.; Jabbour, Elias; Albitar, Maher et al.
In: American journal of hematology, Vol. 94, No. 2, 02.2019, p. 257-265.

Research output: Contribution to journal › Review article › peer-review

Short, NJ , Jabbour, E, Albitar, M, de Lima, M, Gore, L, Jorgensen, J, Logan, AC, Park, J, Ravandi, F, Shah, B, Radich, J & Kantarjian, H 2019, 'Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts', American journal of hematology, vol. 94, no. 2, pp. 257-265. https://doi.org/10.1002/ajh.25338

@article{e0e2e99fe5ae47de8bdebab09536f263,

title = "Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts",

abstract = "Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.",

author = "Short, {Nicholas J.} and Elias Jabbour and Maher Albitar and {de Lima}, Marcos and Lia Gore and Jeffrey Jorgensen and Logan, {Aaron C.} and Jae Park and Farhad Ravandi and Bijal Shah and Jerald Radich and Hagop Kantarjian",

note = "Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",

year = "2019",

month = feb,

doi = "10.1002/ajh.25338",

language = "English (US)",

volume = "94",

pages = "257--265",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia

T2 - A consensus of North American experts

AU - Short, Nicholas J.

AU - Jabbour, Elias

AU - Albitar, Maher

AU - de Lima, Marcos

AU - Gore, Lia

AU - Jorgensen, Jeffrey

AU - Logan, Aaron C.

AU - Park, Jae

AU - Ravandi, Farhad

AU - Shah, Bijal

AU - Radich, Jerald

AU - Kantarjian, Hagop

PY - 2019/2

Y1 - 2019/2

N2 - Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.

AB - Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.

UR - http://www.scopus.com/inward/record.url?scp=85057330448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057330448&partnerID=8YFLogxK

U2 - 10.1002/ajh.25338

DO - 10.1002/ajh.25338

M3 - Review article

C2 - 30394566

AN - SCOPUS:85057330448

SN - 0361-8609

VL - 94

SP - 257

EP - 265

JO - American journal of hematology

JF - American journal of hematology

IS - 2

ER -

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this